Monopar reports Phase 3 trial shows ALXN1840 beats standard care for neurologic Wilson disease
Filed April 20, 2026 · Period ending April 19, 2026 · ~1 min read
2 material changes detected in this filing.
Create a free account to read the full summary — it takes 30 seconds.
Partner
Trade MNPR commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 3, 2026 2:11 AM